About semaglutide

The approved doses for subcutaneous injection of semaglutide once a week are 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg， The trade name is Ozempic. As an auxiliary means of diet and exercise, it can improve the blood sugar control of patients with type 2 diabetes and reduce the risk of major adverse cardiovascular events in patients with type 2 diabetes and patients with diagnosed cardiovascular diseases.

Novo Nordisk also sells Smeglutide under the trade names of Rybelsus oral tablet (for treatment of type 2 diabetes) and Wegovy injection (for chronic weight management). The company holds approximately 54% of the value market share in the GLP-1 field, mainly due to its semaglutide drug.